Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycop...

Full description

Saved in:
Bibliographic Details
Main Authors: Joseph Jelinski, Monika M. Kowatsch, Marc-Alexandre Lafrance, Alice Berger, Jannie Pedersen, Hiva Azizi, Yue Li, Florine Scholte, Alejandro Gomez, Natasha Hollett, Toby Le, Matthew Wade, Hugues Fausther-Bovendo, Marc-Antoine de La Vega, George Babuadze, Ara, Claude Lamarre, Trina Racine, Chil-Yong Kang, Xiao-Jian Yao, Galit Alter, Eric Arts, Keith R. Fowke, Gary P. Kobinger
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2251595
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850111177184509952
author Joseph Jelinski
Monika M. Kowatsch
Marc-Alexandre Lafrance
Alice Berger
Jannie Pedersen
Hiva Azizi
Yue Li
Florine Scholte
Alejandro Gomez
Natasha Hollett
Toby Le
Matthew Wade
Hugues Fausther-Bovendo
Marc-Antoine de La Vega
George Babuadze
Ara
Claude Lamarre
Trina Racine
Chil-Yong Kang
Xiao-Jian Yao
Galit Alter
Eric Arts
Keith R. Fowke
Gary P. Kobinger
author_facet Joseph Jelinski
Monika M. Kowatsch
Marc-Alexandre Lafrance
Alice Berger
Jannie Pedersen
Hiva Azizi
Yue Li
Florine Scholte
Alejandro Gomez
Natasha Hollett
Toby Le
Matthew Wade
Hugues Fausther-Bovendo
Marc-Antoine de La Vega
George Babuadze
Ara
Claude Lamarre
Trina Racine
Chil-Yong Kang
Xiao-Jian Yao
Galit Alter
Eric Arts
Keith R. Fowke
Gary P. Kobinger
author_sort Joseph Jelinski
collection DOAJ
description Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.
format Article
id doaj-art-ac4f6afa4e50490f8eb8b4863aced04d
institution OA Journals
issn 2222-1751
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Emerging Microbes and Infections
spelling doaj-art-ac4f6afa4e50490f8eb8b4863aced04d2025-08-20T02:37:39ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112210.1080/22221751.2023.2251595Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigenJoseph Jelinski0Monika M. Kowatsch1Marc-Alexandre Lafrance2Alice Berger3Jannie Pedersen4Hiva Azizi5Yue Li6Florine Scholte7Alejandro Gomez8Natasha Hollett9Toby Le10Matthew Wade11Hugues Fausther-Bovendo12Marc-Antoine de La Vega13George Babuadze14Ara15Claude Lamarre16Trina Racine17Chil-Yong Kang18Xiao-Jian Yao19Galit Alter20Eric Arts21Keith R. Fowke22Gary P. Kobinger23Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USADepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, CanadaFaculty of Medicine, Université Laval, Quebec City, CanadaDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, CanadaAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, CanadaDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, CanadaDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, CanadaDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, CanadaDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, CanadaDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, CanadaDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, CanadaAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, CanadaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USADepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USADepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USADepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USAAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, CanadaAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, CanadaDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, CanadaDepartment of Medical Microbiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, CanadaRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USADepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, CanadaDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, CanadaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USADespite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.https://www.tandfonline.com/doi/10.1080/22221751.2023.2251595HIVimmunodeficiencyvaccineprophylaxisNHPT-cell
spellingShingle Joseph Jelinski
Monika M. Kowatsch
Marc-Alexandre Lafrance
Alice Berger
Jannie Pedersen
Hiva Azizi
Yue Li
Florine Scholte
Alejandro Gomez
Natasha Hollett
Toby Le
Matthew Wade
Hugues Fausther-Bovendo
Marc-Antoine de La Vega
George Babuadze
Ara
Claude Lamarre
Trina Racine
Chil-Yong Kang
Xiao-Jian Yao
Galit Alter
Eric Arts
Keith R. Fowke
Gary P. Kobinger
Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
Emerging Microbes and Infections
HIV
immunodeficiency
vaccine
prophylaxis
NHP
T-cell
title Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
title_full Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
title_fullStr Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
title_full_unstemmed Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
title_short Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
title_sort rhesus macaques show increased resistance to repeated shiv intrarectal exposure following a heterologous regimen of rvsv vector vaccine expressing hiv antigen
topic HIV
immunodeficiency
vaccine
prophylaxis
NHP
T-cell
url https://www.tandfonline.com/doi/10.1080/22221751.2023.2251595
work_keys_str_mv AT josephjelinski rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT monikamkowatsch rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT marcalexandrelafrance rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT aliceberger rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT janniepedersen rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT hivaazizi rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT yueli rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT florinescholte rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT alejandrogomez rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT natashahollett rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT tobyle rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT matthewwade rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT huguesfaustherbovendo rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT marcantoinedelavega rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT georgebabuadze rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT ara rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT claudelamarre rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT trinaracine rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT chilyongkang rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT xiaojianyao rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT galitalter rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT ericarts rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT keithrfowke rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen
AT garypkobinger rhesusmacaquesshowincreasedresistancetorepeatedshivintrarectalexposurefollowingaheterologousregimenofrvsvvectorvaccineexpressinghivantigen